Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)
The BAC will advise the company on business collaborations, communications and interactions with the Federal Government
PRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the company's Business Advisory Committee (BAC), where she will serve as the Chairperson.
Lori McNeill has over 20 years' experience in the healthcare industry, 13 of which were at Pfizer that included working as the Chief of Staff of Global Operations in the Integrated Health Business unit. She additionally had responsibilities in senior marketing and managing operations. Ms. McNeill has held senior executive position at two startup companies and now as an entrepreneur heads a management consulting company. She has been recognized by several institutions: Ranked in Top 100 Global Women in Leadership – Global Council for the Promotion of International Trade, 2021; Changemakers Summit Award Winner, 2021; The State of Women in Leadership – Cover article for HR.com, 2020; and Pfizer International Innovation Excellence Award, 2011 and is currently Global Chairperson of Womenomics.
Sonnet's BAC will operate as an external body, guiding the company on strategic matters including external collaborations, communications and connecting with government programs, such as the Cancer Moonshot initiative. The BAC will consist of a senior pharma executive from Pfizer, a former congressman with over eight years' experience on Capitol Hill, a former White House aide, a successful entrepreneur and Sonnet's investor relations team. The role of the committee will be to assist in partnering efforts and to elevate the company's profile in the field of immune oncology through communication and leveraging the current and upcoming corporate milestones.
"We believe the addition of Lori to the Board, combined with her oversight of the Business Advisory Committee, can further enhance and differentiate the company's operations, as we continue to elevate our standing in the field of immune oncology. This is particularly important in the context of having multiple clinical trials underway that we expect will be yielding data in the coming quarters," said Pankaj Mohan, Ph.D., Sonnet's Founder and Chief Executive Officer.
"This is certainly an exciting time at Sonnet and I am humbled by the opportunity to work with the company on its differentiated approach to innovating oncology therapeutics. As one of my primary responsibilities will be to chair the Business Advisory Committee, I will be leveraging my prior marketing experience to help raise awareness of the FHAB technology, with the intention of generating greater recognition for what I believe to be an exciting biotechnology platform." commented Ms. McNeill.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Sonnet BioTherapeutics Investor Contact
Michael V. Morabito, Ph.D.
Solebury Strategic Communications
917-936-8430
mmorabito@soleburystrat.com
SOURCE: Sonnet BioTherapeutics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/717339/SonnetBioTherapeuticsAppoints-Ms-Lori-McNeill-to-the-Board-of-Directors-and-Formalizes-the-Companys-Business-Advisory-Committee
Related Quotes
In this article, we will look at the 10 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can also take a look at 5 Best Biotech Stocks Under $10. The Global Biotech Industry According to an industry analysis report […]
The mortgage REIT completed a reverse split on Friday, so it's the first trading day post-split. A stock decline in this situation isn't odd at all.
In the early days of the pandemic, if there was one coronavirus vaccine stock investors were betting on, it was Novavax (NASDAQ: NVAX). The biotech stock soared more than 2,700% in 2020 as it developed its vaccine candidate. In the same timeframe, Pfizer shares hardly budged.
In this article, we will take a look at the 10 Quality Stocks to Buy with Shares Down Over 30% YTD. To skip our analysis of the iShares MSCI USA Quality Factor ETF, its performance, and weighting of the components, you can go directly to see the 5 Quality Stocks to Buy with Shares Down […]
The selling in stock markets looks poised to continues, warns veteran strategist Sam Stovall.
(Bloomberg) — John Paulson became a billionaire after his hedge fund effectively shorted more than $25 billion of mortgage securities at the dawn of the global financial crisis. As he sizes up yet another frothy housing market some 15 years later, the founder of Paulson & Co. says another downturn in US home prices may be in the cards — but the banking system is in a much better condition to handle it. Paulson sat down with Bloomberg for a wide-ranging interview at the Union League of Philadel
In this article, we discuss the 10 best oil stocks to buy according to hedge funds. If you want to read about some more oil stocks, go directly to 5 Best Oil Stocks To Buy According To Hedge Funds. The oil sector has rebounded from the lows of the pandemic this year and prices have […]
Shares of the big-data software company Palantir (NYSE: PLTR) gained as much as 5.8% today after the company announced that the Department of Homeland Security renewed a five-year contract with the company. Palantir's stock was up by 2.8% as of 3:20 p.m. ET. Palantir's stock initially got a boost this morning after the company said that the Department of Homeland Security renewed its contract to support Homeland Security Investigations (HSI) using the company's software.
Zacks.com users have recently been watching Energy Transfer LP (ET) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors need to pay close attention to NVIDIA (NVDA) stock based on the movements in the options market lately.
With time, Shopify (NYSE: SHOP) has the potential to be one of them. Diving into the numbers shows how much momentum the company has lost and what it can do to turn things around. The company bet — by hiring staff and building out infrastructure — that the pandemic permanently accelerated e-commerce by five to 10 years.
Shares of enterprise software star Snowflake (NYSE: SNOW) fell today, down 4.1% as of the end of trading — much more than the broader markets. Snowflake is perhaps one of the best-performing businesses in the enterprise software space. The Federal Reserve held its September meeting last week, whereby Fed governors gave their projections for interest rates hikes in the near and medium term.
There's nothing like a bear market to remind S&P 500 investors how low stocks can go. And it's a surprisingly low number per share.
After a grisly 1H22 which represented the stock market’s worst performance since 1970, the second half is shaping up to be a bit of a disappointment too. After clawing back some of the losses, it’s been onto the slide again with the S&P 500 almost back to the mid-June lows. The bad news, according to billionaire investor Carl Icahn, is that things could still get worse from here. “I think a lot of things are cheap, and they’re going to get cheaper,” said Icahn, pointing to the economic malaise,
Dow Jones futures were little changed ahead of Tuesday's open. The Dow Jones Industrial Average finished in a bear market Monday.
Shares of the Trump-linked Digital World Acquisition Corp. are bouncing back after sliding earlier Monday when investors began pulling out of the stock.
Axsome Therapeutics' solid gains of 42% this year came with the hope that its two new products would bring in plenty of revenue in the next few years. Last month, the U.S. Food and Drug Administration (FDA) approved its drug Auvelity for treating major depressive disorder (MDD).
(Bloomberg) — The US dollar’s recent rally is creating an “untenable situation” for risk assets including stocks, and in the past this kind of dollar strength has led to some kind of financial or economic crisis, according to one of Wall Street’s most vocal bears.Most Read from BloombergJohn Paulson on Frothy US Housing Market: This Time Is DifferentUK Market Selloff Slams Gilts, Pound, Piling Pressure on BOEWall Street Banks Prep for Grim China Scenarios Over TaiwanBank of England Says Paper B
The S&P 500 is approaching an important level to watch beyond its 2022 low, as investors anticipate a spike in jobless claims amid recession fears and soured sentiment in the U.S. stock market, according to an RBC Capital Markets note.
These rock-solid income stocks, with yields ranging from 5% to 7%, can pad aged investors' pocketbooks while making them richer.